Immunocore director granted 27,492 share options

Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares.

Rhea-AI Filing Summary

Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036, according to the Form 4.

The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service through the vesting date. After this grant, the filing shows 27,492 derivative securities held directly.

Insider Trade Summary

Grant/Award: 27,492 shares

Grant/Award 1 txn

Insider Herbst Roy Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	27,492	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 27,492 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 27,492 options Exercise price: $28.52 per share Underlying shares: 27,492 ordinary shares +2 more

5 metrics

Options granted 27,492 options Share Option (Right to Buy) granted to director

Exercise price $28.52 per share Conversion or exercise price of options

Underlying shares 27,492 ordinary shares Shares subject to the option award

Expiration date May 26, 2036 Option expiration

Post-transaction derivatives 27,492 securities Total derivative securities following transaction

Key Terms

Share Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)" for the reported transaction"

exercise price financial

"conversion_or_exercise_price of $28.5200 per share for the options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"options have an expiration_date of 2036-05-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"the shares subject to the option award shall vest at the earlier of certain dates"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunocore (IMCR) director Roy Steven Herbst report on this Form 4?

Roy Steven Herbst reported receiving 27,492 share options in Immunocore Holdings plc. These options give him the right to buy 27,492 ordinary shares at a fixed exercise price of $28.52, subject to vesting and expiration terms set out in the award.

What are the key terms of Roy Steven Herbst’s Immunocore share option grant?

The option grant covers 27,492 underlying ordinary shares at an exercise price of $28.52 per share. The options expire on May 26, 2036 and vest upon the earlier of May 27, 2027 or immediately before Immunocore’s next annual general meeting, subject to continuous service.

When do the Immunocore share options granted to Roy Steven Herbst vest?

The options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on Roy Steven Herbst maintaining continuous service with the company through that applicable vesting date, as described in the Form 4 footnote.

How many Immunocore derivative securities does Roy Steven Herbst hold after this transaction?

After this grant, the Form 4 shows Roy Steven Herbst holding 27,492 derivative securities. These represent share options, each linked to one underlying ordinary share of Immunocore, and reflect his direct holdings following the reported award transaction.

Is Roy Steven Herbst’s Immunocore Form 4 transaction an open-market stock purchase?

No, the Form 4 reports a grant of share options classified as a derivative award, not an open-market purchase of shares. The transaction code "A" and description indicate a grant or award acquisition rather than buying shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 07:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herbst Roy Steven

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON OXFORDSHIRE OX14 4RY

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$28.52	05/27/2026		A		27,492		(1)	05/26/2036	Ordinary Shares	27,492	$0	27,492	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)